New pages

Jump to navigation Jump to search
New pages
Hide registered users | Hide bots | Show redirects
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

20 April 2025

  • 14:5114:51, 20 April 2025 Avapritinib (hist | edit) [5,278 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid AfkhamiArdakani |genericName=Avapritinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutations, Advanced systemic mastocytosis (AdvSM), and Indolent systemic mastocytosis (ISM) |adverseReactions=Nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, edema, decreased appetite, cognitive impairment, dizziness, rash, and h...")
  • 14:0314:03, 20 April 2025 Olanzapine and samidorphan (hist | edit) [57,005 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Olanzapine and samidorphan in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guidel...")
  • 05:5405:54, 20 April 2025 Vanzacaftor, tezacaftor, and deutivacaftor (hist | edit) [62,951 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Vanzacaftor, tezacaftor, and deutivacaftor in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-La...")

15 April 2025

  • 11:4311:43, 15 April 2025 Vyloy (hist | edit) [900 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Vyloy in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Vyloy in adult pa...")

13 April 2025

  • 16:4316:43, 13 April 2025 Olipudase alfa (hist | edit) [50,137 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Olipudase alfa in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supporte...")
  • 16:4216:42, 13 April 2025 DaxibotulinumtoixnA-lanm (hist | edit) [34,192 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of DaxibotulinumtoixnA-lanm in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guidelin...")
  • 16:4116:41, 13 April 2025 Eflapegrastim (hist | edit) [23,283 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Eflapegrastim in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported...")
  • 16:3816:38, 13 April 2025 Gadopiclenol (hist | edit) [29,538 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Gadopiclenol in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported...")
  • 16:3716:37, 13 April 2025 Oomidenepag isopropyl ophthalmic solution (hist | edit) [17,583 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Oomidenepag isopropyl ophthalmic solution in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Lab...")
  • 16:3516:35, 13 April 2025 Teclistamab-cqyv (hist | edit) [38,692 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Teclistamab-cqyv in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Teclis...")
  • 16:3516:35, 13 April 2025 Mirvetuximab soravtansine-gynx (hist | edit) [42,612 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Mirvetuximab soravtansine-gynx in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Gu...")
  • 16:3416:34, 13 April 2025 Teplizumab-mzwv (hist | edit) [32,073 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Teplizumab-mzwv in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Support...")
  • 16:3216:32, 13 April 2025 Hyperpolarized Xe-129 (hist | edit) [20,040 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Hyperpolarized Xe-129 in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-S...")
  • 16:2616:26, 13 April 2025 Flotufolastat F 18 (hist | edit) [22,497 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Flotufolastat F 18 in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supp...")
  • 16:2416:24, 13 April 2025 Marstacimab-hncq (hist | edit) [22,860 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Marstacimab-hncq in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppor...")
  • 16:2316:23, 13 April 2025 Zolbetuximab-clzb (hist | edit) [32,109 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Zolbetuximab-clzb in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppo...")
  • 16:2216:22, 13 April 2025 Orlynvah (hist | edit) [934 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Orlynvah in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'...")
  • 16:2216:22, 13 April 2025 Sulopenem etzadroxil, probenecid (hist | edit) [1,054 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Sulopenem etzadroxil, probenecid in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–...")
  • 14:2214:22, 13 April 2025 Ubrogepant (hist | edit) [5,022 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Ubrogepant |aOrAn=a |drugClass=Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist |indicationType=treatment |indication=migraine with or without aura in adults. |adverseReactions=Somnolence, Nausea, Dry mouth, Hypersensitivity reactions including rash, urticaria, and facial edema. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color...")
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)
Retrieved from "https://www.wikidoc.org/index.php/Special:NewPages"